康莱特对临床肺腺癌患者生存素表达的影响

《康莱特对临床肺腺癌患者生存素表达的影响》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、授予单位代码10089学号或申请号14312中国图书分类号R734.2HebeiMedicalUniversity硕士学位论文学术学位康莱特对临床肺腺癌患者生存素表达的影响研究生：蔡宝松导师：杨立伟教授专业：胸外科二级学院：第四医院2018年3月目录中文摘要·············································································1英文摘要·············································································4英文缩

2、写·············································································7研究论文康莱特对临床肺腺癌患者生存素表达的影响前言·············································································8材料与方法····································································8结果··································

3、···········································11附图·············································································13附表·············································································15讨论·············································································18结论··

4、···········································································21参考文献·······································································21综述康莱特注射液治疗肿瘤的研究进展···································25致谢··················································································

5、·33个人简历·············································································34康莱特对临床肺腺癌患者生存素表达的影响摘要目的：肺癌是我国最常见的恶性肿瘤之一，发病率逐年增加并呈年轻化趋势。除手术、放疗、化疗这些传统的恶性肿瘤治疗手段，分子生物学的发展及靶向治疗应用成为肺癌治疗的里程碑，但仍难以解决部分肺癌的转移与复发。近年大量研究发现中医药能够个体化、多层次、多靶点控制肿瘤生长、对抗转移、减少复发。临床实践中发现康莱特注射液（Kanglaite，KLT）对肺癌有抗癌作用，并且无毒副作用

6、。本研究应用免疫组化方法分析应用KLT治疗前后肺腺癌组织中生存素(Survivin)的变化，进一步分析KLT的作用机制。方法：1收集术前经病理确诊为肺腺癌患者65例，排除以下情况：①术前已经进行放疗及化疗的患者；②术中未能将肿瘤切除的患者；③术前术后病理不一致的患者。在患者病理确诊后，于术前给予患者应用KLT，200毫升/天，连续10天。取用药前及用药后肿瘤组织进行检测。用药前肿瘤组织为未使用KLT之前经支气管镜或者CT引导下经皮肺穿刺取得的病理组织；用药后肿瘤组织为术后从肿瘤组织上直接取得的病理组织。2应用免疫组化方法检测患者用药前后肿瘤组织Survivin的表达。采用自身对

7、照，观察用药前后肿瘤组织Survivin的表达变化。3采用SPSS17.0统计软件包，将实验数据输入计算机处理分析。对2计数资料采用χ检验。检验结果以P＜0.05为差异有统计学意义。结果：1.用药后不同性别患者肿瘤组织中生存素表达阳性率差异无统计学意义（P>0.05)，用药前不同性别患者肿瘤组织中生存素表达阳性率差异无统计学意义（P>0.05)。2.用药后不同年龄段患者肿瘤组织中生存素表达阳性率差异无统计学意义（P>0.05)，用药前不同年龄段患者肿瘤组织中生存素表达阳性率差异无统计学意义（